1. Chairman’s Welcome & Opening Remarks Mumbai, India – 24 th July 2007

2. Education Issues

3. IP Issues “In our judgment, arguing that IP issues constrain you from having aggressing China & India strategies is a cop out” “It is also important to note that governments in both China & India are becoming increasingly serious about enforcement Of laws on IP” Source: Wall Street Journal, May 03, 2007

4. CRAMS Issues 71% 16% 13% CRAMS market in India 71% contract manufacturing 16% clinical research - $143 m 13% contract research - $116 m -$0.9 b in 2006, +43% growth - Forecast to reach $6.6 b in 2013 Source: Frost & Sullivan Business Today, 20 th May 2007

5. Clinical Research Issues -100,000 patients -3000 sites -50,000 clinical research professionals -400 CT applications by regulatory authorities Source: Ernst & Young Market size > $ 1b by 2010 Source: McKinsey Source: Business Standard, 9 th May 2007

6. Regulatory Issues Pharmacovigilance -Sweden 250/300 regulators -India 25 regulators Source: Pharma Market Letter, 23 rd April’ 2007 On Site Inspection & real time audits of CT -30 investigators -First inspection to start in July Source: MINT, 6 th June’ 2007 On line clinical registry -Share data with 26 ICMR institutes on line -Pilot scale to start in July -Only primary date to be held Source: Business Standard, 9 th March’ 2007

7. Medical Tourism Issues -Tourists from UK, RSA, Canada, Malaysia -Market size estimated to be $ 1.5b by 2010

8. Questions for today’s session Is the current mood towards India sustainable? How can India improve? How to keep India clinical trials ethical? How to address safety concerns? How to measure ROI in outsourcing?

9. Thank You